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Introduction 
The meniscus is a fibrocartilagenous tissue that functions 
to stabilise the knee joint, to transmit load and to absorb 
shock. Meniscal injuries are common and the incidence of 
these injuries is increasing, particularly within an ageing 
population. In addition to the direct pain caused by meniscal 
damage and degeneration, mensical pathology leads to 
osteoarthritis (OA) of the knee.   
Different tissue engineering strategies are currently being 
developed to treat damaged menisci including the use of 
decellularised allogeneic menisci [1], synthetic scaffolds [2, 3] 
and biological scaffolds [4, 5]. Whilst biological scaffolds are 
biocompatible and biodegradable, they often do not have the 
necessary biomechanical properties required to withstand the 
forces experienced by the meniscus. The meniscus requires 
high circumferential tensile strength to resist the compression 
and extrusion from the joint space that loading induces [6]. It 
has been shown that a biphasic collagen/synthetic polymer 
fibre scaffold mimics the tensile and hoop stress behaviour of 
normal meniscus under compressive loading [6], indicating 
that a composite scaffold might provide the biomechanical 
strength needed. Our group has developed collagen fibres for 
a range of applications [7, 8], which can be incorporated into a 
collagen sponge to increase strength [9]. We have previously 
described the production of a novel collagen sponge 
reinforced with collagen fibres that can support meniscal cell 
growth in vitro [10]. 
Whilst a scaffold will provide a structural support for the 
ingrowth of meniscal repair tissue, tissue engineering 
strategies have shown that incorporation of biological factors 
onto scaffolds can promote healing in the meniscus. Studies 
have shown that the addition of Platelet Rich Plasma (PRP) 
to scaffolds can enhance meniscal repair [11, 12]. We have 
previously demonstrated that the combination of collagen 
scaffolds with PRP allows adsorption and extended release of 
biologically active growth factors and supports meniscal cell 
growth in vitro [10, 13]. 
The aims of this study were i) to investigate whether a 
novel biphasic collagen scaffold supports meniscal repair in 
an ovine meniscal defect model in vivo, ii) to investigate 
meniscal cell ingrowth and ECM production in an ex-vivo 
model and iii) to investigate the effect platelet rich plasma 
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(PRP) on the response of meniscal elements to the scaffold. 
Materials and Methods 
Animals This study received approval from the UK Home 
Office and local research ethics committee. Whole ovine 
menisci from healthy stifle joints for the ex vivo models 
(EVM) were obtained from adult (aged 2 – 2.5 years) female 
Welsh Mountain animals euthanized for non-orthopaedic 
reasons (n = 8). For the in vivo study, a total of 36 adult 
female Welsh mountain sheep were used in this study, n = 6 
per treatment group.  
Scaffolds The scaffold used in this study was a collagen 
sponge with 300 µm open pores, reinforced with bands of 
150µm internal strengthening fibres [10]. The scaffold was 
constructed with strengthening fibres oriented so that they 
were the equivalent of parallel to the cranial surface of the 
meniscus (Fig. 1). Scaffolds were sterilised by gamma 
irradiation prior to use. 
Production of PRP 6 ml of sheep blood was collected 
into Acid Citrate Dextrose anticoagulant at a concentration of 
1:10 and then centrifuged at 400g for 10 minutes and plasma 
decanted to remove the red blood cells. The platelets were 
concentrated by centrifugation at 1000g for 15 minutes. 
Platelets were resuspended in 400µls of plasma. PRP cell 
composition profile was examined by fixing PRP in filtered, 
centrifuged and decanted ACDA: 4% PFA: PBS, 1:1:1 
preserving solution for flow cytometery using forward and 
side scatter for cell counts on a Beckman Coulter FC 500 
with analysis on CXP Flowplot.  
Surgical technique. The surgical technique was identical 
in each animal and performed under strict asepsis by a single 
surgeon. Surgery was performed under general anaesthesia. 
The left femoro-tibial joint was opened via a medial 
approach, leaving the medial collateral ligament intact. The 
superior surface of the medial meniscus was exposed and a 3 
mm diameter circular defect was created using a modified 
biopsy punch. Once the defect was created it was either left 
unfilled (‘Defect group’ = Group D), the defect filled with a 
3mm diameter scaffold plug (‘Scaffold group’ = Group S) or 
the defect filled with a scaffold plug pre-soaked with 
autologous PRP (‘Scaffold + PRP group’ = Group SP). Joints 
were sutured in a routine fashion and the animals allowed to 
fully weight bear post-operatively. The animals were housed 
in large indoor pens for 14 days post-surgery. Subsequently 
they were turned out into fields. Animals were euthanized 
with an overdose of anaesthetic at 8 and 24 weeks 
post-surgery. 
Gait analysis Weight bearing on the operated limb was 
measured before and 2,5 and 8 weeks after surgery using an 
AMTI force plate (BP600600-1000) as described previously 
[10]. The weight bearing on the limb was quantified as N/kg 
body weight for each individual animal and the data 
combined for each group to allow analysis. 
Gross meniscal anatomy Digital images (600 dpi) of 
excised menisci were captured on a flatbed scanner. The 
percentage of the defect infilled with repair tissue at the 
surface was measured via image J software [14]. 
Quantification of meniscal hardness. Meniscal tissue 
hardness (defined as a material’s ability resistance to 
permanent indentation) was tested using a Shore S1 
durometer that has been used previously to measure cartilage 
hardness [15]. A measurement was taken centrally at the 
defect site and 5 mm anterior, posterior to the defect centre 
and at the mid-point of the central region on the superior and 
inferior surfaces and on the superior and inferior surface of 
the medial menisci. A mean hardness score was acquired for 
each meniscus. As a control, the same points were measured 
on the unoperated medial meniscus of the other leg in the 
same animal, with all animals being evaluated individually. 
In the control animals the mean hardness score was allocated 
a value of 100% to represent the normal hardness of the 
tissue. 
Histological examination of the menisci. The meniscus 
was excised and fixed with 4 % paraformaldehyde and 
routinely embedded for wax histology. Sections of the 
menisci at the defect site were stained with Safranin O and 
counter stained with fast green and Gills II Haematoxylin. 
The histological appearance of the meniscus was scored 
using a scoring system described by Zhang [16] (Table 1). 
Antibodies The antibodies used for this study for Western 
blotting were rabbit polyclonal anti-type I collagen (Abcam, 
UK), rabbit monoclonal anti-versican (Abcam, UK), rabbit 
Figure 1. Photograph to show fibre orientation in the scaffold.   
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Table 1 Histological scoring system 
Characteristic Subcategory Score 
Nature of the predominant tissue Typical fibrocartilage 5 
 >50% fibrocartilage 4 
 50% fibrocartilage/50% fibrous tissue or 
scaffold 
3 
 >50% fibrous tissue 2 
 Fibrous tissue 0 
Toluidine blue staining of matrix Normal staining 3 
 Moderate staining 2 
 Slight staining 1 
 None 0 
Surface Smooth and intact 3 
 Superficial lamination 2 
 Slight disruption 1 
 Severe disruption 0 
Integrity Normal structure 2 
 Slight disruption 1 
 Severe disruption 0 
Thickness 75-100% of adjacent tissue 2 
 50-74% of adjacent tissue 1 
 0-49% of adjacent tissue 0 
Bonding to host tissue Bonded 2 
 Partially bonded 1 
 Not bonded 0 
Repair tissue in the defect Normal cell morpholgy and matrix staining 3 
 Cell clustering and normal matrix staining 2 
 Decreased matrix staining 1 
 Poor or no matrix staining 0 
Overall healthy cartilage cell number Similar to normal fibrocartilage 3 
 Slightly less than normal fibrocartilage 2 
 Much less than normal fibrocartilage 1 
 Acellular 0 
Matrix porosity Thick matrix no pores 5 
 Thick matrix some pores 4 
 Semithick matrix with many pores 3 
 Porous matrix 2 
 Fibrous matrix 0 
Maximum possible score  31 
 
monoclonal anti-lumican (Abcam, UK), rabbit monoclonal 
vimentin (Abcam, UK), (rabbit polyclonal anti-smooth 
muscle actin (SMA) (Abcam, UK) and rabbit polyclonal 
anti-GAPDH (Sigma, UK). The antibodies used for this 
study for Immunohistochemistry (IHC) were rabbit 
polyclonal monoclonal anti-mouse types I and II Collagen 
(MP Biomedicals, US) and monoclonal anti-vimentin 
(Dylight 488 conjugated (Abcam, UK). 
Immunohistochemical examination Standard IHC 
techniques were used as previously described [10]. Type I and 
II collagen antibodies (1:200 dilution) were used with a 
biotinyated secondary anti-mouse antibody (Sigma, UK) and 
developed with diaminobenzamine (DAB) to localise types I 
and II collagen. Vimentin (1:200 dilution) was directly 
visualised under fluorescent microscopy. 
Ex vivo model (EVM) Preparation Isolated meniscus 
were incubated in culture medium (DMEM containing 10% 
foetal calf serum, 100iu/100ug/ml penicillin/streptomycin, 
10ug/ml Gentamycin, 2.5ug/ml Amphotericin B and 20ug/ml 
ascorbate-2-phosphate (Sigma)) for 24hrs prior to 
exerimental manipulation. Two types of EVM were created; 
1. Internal where a scaffold is surrounded with tissue to 
directly mimic the in vivo experiments and 2. External where 
an explant is surrounded by scaffold (Fig. 2). Internal EVMs 
Figure 2. Photographs to show construction of ex vivo models 
(EVM). A and C Internal EVMs in which a 3mm diameter plug of 
scaffold has been inserted into a 3mm diameter hole in an adult 
ovine meniscus. A Examples of constructs, C a close up picture of 
one construct. B and D External EVM in which in which 3mm 
diameter plugs of meniscus (derived from making the holes seen in 
A and C) have been inserted into 3mm diameter holes in the 
scaffold. B Examples of constructs, D a close up picture of one 
construct. 
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were created by removing full depth 3mm diameter meniscal 
cartilage explants from normal meniscal tissue using a biopsy 
punch (Kai Medical). Scaffold discs (3mm diameter and 
4mm depth) were soaked in culture media or PRP for 5 
minutes and inserted into the holes in the meniscus. External 
EVMs were constructed by using the 3mm diameter explants 
derived during the construction of the IEVMs and placing 
them into 3mm diameter holes made in scaffold material. 
EVM were cultured in 12 well plates containing complete 
media for up to 28 days. 
Cell Culture Isolated meniscal cells were obtained so that 
a population of ‘native’ meniscal cells were available for 
protein analysis. Mensical cells were prepared by finely 
chopping fresh ovine meniscal cartilage and digesting 
overnight at 37oC with shaking in 0.2% collagenase A 
(Sigma). Cells were washed and plated out in culture 
medium as above and first passage cells were extracted for 
western blotting as detailed below. 
Western Blotting At EVM harvest, scaffolds and tissue 
were separated. Proteins were extracted from scaffolds and 
cartilage in cell extraction buffer (Life Technologies) 
containing a proteinase inhibitor cocktail before running on 
SDS electrophoresis and Western blotting as previously 
described [17].  
Histology At 3, 10, 17 and 24 days in culture, EVMs were 
fixed in 4% paraformaldehyde and snap-frozen. Sections 
(8µm thick) were obtained and stained with Vectashield 
(Vector Laboratories) containing 
4',6-diamidino-2-phenylindole (DAPI) to stain the cell 
nuclei. Images were acquired and the distance that the 
meniscal cells had migrated in to the scaffold calculated 
using ImageJ software. The mean value of 3 different EVM 
was calculated. 
Immunhistochemistry After 24 days EVMs were 
harvested for immunohistochemistry. Frozen sections (8µm 
thick) were fixed using a 1:1 solution of acetone and 
methanol before probing with primary antibodies and 
FITC-conjugated secondary antibodies and mounting in 
Vectashield (Vector Laboratories) containing DAPI. 
Results 
In vivo model  
PRP analysis The PRP preparations contained 1.37 x106 
(+/- 4.6 x 104) platelets per microlitre compared to whole 
blood samples which contained 1.8 x 105 (+/- 1.1 x105) 
platelets per microlitre. 
Gait analysis The weight bearing on the operated limb 
was measured before surgery, and 2, 5 and 8 weeks post 
surgery and expressed as N/kg. Pre-surgery, there was no 
difference between the experimental groups, with an average 
N/kg of 5.6 of weight born on the leg that was subsequently 
operated on. Measurements of weight bearing at 2w 
post-surgery did not find any significant differences between 
groups or compared to pre surgical values. Subsequent 
measurements of weight bearing did not find any significant 
differences between groups or time points (Fig. 3). 
Gross morphology and tissue hardness. At 8 and 26 
weeks post-surgery joints were recovered and opened. There 
was no evidence of increased synovial fluid or synovitis in 
the joint. Mensical defects were still present in operated 
menisci (Fig. 4). The defects were seen as disruptions of the 
meniscal surface with new tissue infilling the defect regions 
in all groups. At 8w there was no difference in percentage 
surface infill between groups, however, at 26w there was a 
significant increase in surface infill in Group SP compared to 
Group S (Fig 4).  
Tissue hardness was measured by Durometer indentation 
testing at 8 and 26 weeks post-surgery (Fig. 5). The average 
Figure 3. Weight bearing on the operated leg pre surgery, 2, 5 
and 8 weeks post surgery in the three groups of animals 
described in this study normalised to the pre-surgery weight 
bearing. Measurements of weight bearing at 2w post-surgery did not 
find any significant differences between groups or compared to pre 
surgical values. Subsequent measurements of weight bearing did 
not find any significant differences between groups or time points. 
These results indicate that the surgical procedure was mild and did 
not cause a significant lameness post-surgery. There was not 
alteration in the weight bearing of operated legs between groups. D - 
defect only, S - defect + scaffold, SP - defects + scaffold + PRP. 
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hardness measurement for the control (unoperated, 
contralateral limb) meniscus was 59.1 +/- 6 at 8 weeks 
post-surgery and 63.8 +\- 7.2 at 26 weeks post-surgery. At 8 
weeks post-surgery, there was a significant difference in the 
hardness of all 3 operated groups compared to the 
unoperated, control meniscus, however, there was no 
difference between the groups. At 26 weeks post-surgery the 
tissue hardness had increased compared to the hardness 
measured at 8 weeks post-surgery, however, again, there was 
no difference between the groups and no statistical difference 
between the groups and the unoperated, control meniscus 
(Fig. 5). 
Histological assessment of meniscal repair Subjectively, 
there was good infill of tissue into scaffolds at both 8 and 
Figure 4. Photographs of menisci recovered from animals 8w post surgery. A control meniscus from unoperated leg to show normal 
appearance of the ovine meniscus. B meniscus from animal in which only a defect was made in the meniscus (Group D), C meniscus from 
animal in which the defect in the meniscus was treated with a scaffold (Group S), D meniscus from animal in which the defect in the 
meniscus was treated with a scaffold plus PRP (Group SP). These menisci are the median scoring sample (histological scoring) from each 
of their respective treatment groups. In each meniscus the operated site is indicated with a black line. 3b. Graph to show the percentage 
tissue infill at the defects at 8w and 26w post surgery. There is a statistically significant (p<0.05) difference between Group S and Group 
SP in the 26w operated animals, indicating that the addition of PRP to the scaffold has enhanced the amount of surface tissue infill in this 
model. D - defect only, S - defect + scaffold, SP - defects + scaffold + PRP. 
 
 
 
 
Figure 5. Graph to show the hardness of the repair tissue in the 
meniscus at 8w and 26w post-surgery. At 8 weeks post-surgery, there was 
a significant difference in the hardness of all 3 operated groups compared to 
the unoperated, control meniscus, however, there was no difference between 
the groups.  At 26 weeks post-surgery the tissue hardness had increased 
compared to the hardness measured at 8 weeks post-surgery, however, 
again, there was no difference between the groups and no statistical 
difference between the groups and the unoperated, control meniscus. 
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26w (Fig. 6). The repair tissue stained extensively with 
Safranin O suggesting the presence of proteoglycan within 
the defect site. Defects were scored to provide quantitative 
data on the degree of healing. In the histological sections at 
8w it was seen that the addition of PRP to the scaffold 
(Group SP) significantly increased the healing (Fig. 7) 
compared to Groups D and S. By 26w there was no 
difference between experimental groups (Fig. 7). Remnants 
of scaffold material was detected in all Group S and SP at 8w 
but not at 26w post-surgery.  
Figure 6. Histology and Immunohistochemistry of meniscal tissues. A-F Safranin O stained whole menisci. A, B and C retrieved 8w 
post surgery, D, E and F retrieved 26w post surgery.  A and D Group D (Defect), B and E Group S (Scaffold placed in defect), C and F 
Group SP (Scaffold plus PRP placed in defect). There is tissue infill in each of these menisci. The original defect is indicated with a line. In 
the 26w post surgery group there is more maturation of the extracellular matrix. In each section the black arrow indicates the position and 
orientation of the defect and each section represents the median section identified following quantitative scoring of healing. G 
Representative example of type I collagen staining in repairing meniscus, H Representative example of versican staining in repairing 
meniscus. In each section the white arrow indicates the position and orientation of the defect. 
 
 
 
Figure 7. Quantitative scoring of repair of meniscal defects. A 8w post surgery, B 
26 weeks post surgery. At 8w post surgery there is a significant increase in histology 
score in the scaffold plus PRP group compared to the control and scaffold only group.  
At 26w post surgery there is no difference between groups. 
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Immunohistochemical assessment of meniscal tissue 
IHC of meniscal ECM markers demonstrated that collagen I 
and versican were present in the meniscus and within the 
healing defect at 8w and 26w post-surgery (Fig.6). An 
increase in vimentin positive cells was detected in the 
regions of the defects of samples at 8w, this difference was 
not apparent at 26w (Fig. 8).  
Ex vivo models 
Histology In histological sections, cells were visible both 
around the cut edges of EVM and within the scaffolds at all 
time points studied. The distance that the cells had migrated 
into the scaffold was calculated. In the presence of PRP cells 
had migrated further at all time points studied compared to 
scaffold alone EVM. In plain EVM, cells had migrated with 
a mean distance of 1500µm (+\- 175) into the scaffold, 
whereas in the presence of PRP cells had migrated 2950µm 
(+\- 297) into the scaffold by 24 days. (Fig. 9). 
Western Blotting Western blots of extracts of meniscal 
tissues and cells that had been enzymatically isolated showed 
that they contained collagen type I and versican which are 
markers of meniscal ECM. Cells extracted from within 
internal and external EVMs also demonstrated the presence 
of these markers (Fig. 9). In addition to identifying markers 
of meniscal ECM proteins in the extracts from the scaffolds, 
Western blotting also identified SMA, lumican and vimentin 
within the meniscal tissue, cells and in the scaffolds (Fig. 
10). 
Analysis of the Western blots using densitometry 
demonstrated that the addition of PRP to the scaffold 
Figure 8. Vimentin immunohistochemistry (IHC) in repairing 
meniscus. in the meniscus. A 8w post surgery, B 26w post 
surgery.  In A there is an increase in the green fluorescent signal 
indicating the presence of vimentin at the edge of the meniscus 
adjacent to and extending through the repair tissue. In both sections 
the white arrow indicates the position and orientation of the defect. 
 
 
 
Figure 9. Graph to show quantification of distance that cells had 
migrated into scaffolds in ex vivo models. D= day, S- = scaffold 
alone, S+ scaffold plus meniscus, SP+ scaffold plus PRP plus 
meniscus. In Group S EVM, cells had migrated with a mean distance 
of 1500µm (+\- 175) into the scaffold, whereas in the presence of 
PRP (Group SP) cells had migrated 2950µm (+\- 297) into the 
scaffold. 
 
Figure 10. Western blots of meniscal tissue, meniscal cells, and 
scaffolds removed from external ex vivo models (two different 
samples). Each sample was Western blotted for smooth muscle 
actin (SMA), vimentin, versican, type I collagen, lumican. Cells 
obtained from within the scaffold produced collagen type I and 
versican, as is found in mature meniscus tissue. The production of 
luminca, also present in mature meniscal tissue was low in cells 
within the scaffold but increased in the presence of platelet rich 
plasma (PRP). SO = Scaffold only, PRP = Scaffold + PRP, MC = 
Meniscal calls, MT = Meniscal tissue. 
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enhanced SMA, lumican and vimentin in the scaffolds (Fig 
11), with most effects being detected in the external EVM. 
Statistically significant data was achieved for the markers of 
cell migration/repair and for the overall cell number 
(GAPDH) in the external EVM. 
Discussion 
In this study we have demonstrated that a novel biphasic 
collagen scaffold can support meniscal defect repair in an in 
vivo model and support the ingrowth of meniscal cells in an 
ex vivo model. In addition we have demonstrated that the 
addition of PRP significantly enhances mensical cell 
migration and ECM production in vitro and promotes rapid 
defect healing in vivo.  
In order to investigate the biocompatibility of the biphasic 
scaffold, scaffolds were implanted into a circular meniscal 
defect in an ovine model. At 8 and 26w post-surgery 
macroscopically there was comparable tissue infill into the 
repair site in all groups, demonstrating that the scaffold was 
able to support tissue healing. Quantitative analysis of the 
repair tissue showed that, at 8w, there was a significant 
increase in the histology score in the defects treated with 
scaffolds including PRP compared to control (empty) defects 
and scaffolds alone, by 26w no differences were noted. At 
26w the mean histology score for all animals was similar to 
the mean histology score of the scaffold + PRP defects at 8w, 
indicating that the addition of PRP to the scaffolds had 
accelerated the healing more rapidly towards the maximum 
that could be achieved by 26w. These results, i.e. some 
improvement in histology early in the repair process but no 
significant overall in vivo improvement at 26w, illustrate the 
difficulties in interpreting results from experiments 
comparing treatments with and without augmentation of 
PRP. Recent clinical studies have shown both benefit [18] and 
no benefit [19] of augmenting meniscal repair with PRP in 
patients, while animal models have yielded similarly 
opposing results[12, 20] .   
The optimal pre-clinical model for the in vivo evaluation 
of meniscal scaffolds is not defined [21, 22]. Ovine models 
have previously been used to evaluate meniscal repair and 
regenerative strategies [23, 24] and the structural properties and 
physiology of the ovine meniscus are relatively similar to 
that of the human meniscus [22, 25]. It has been reported that 
the ovine meniscus has superior healing capacity compared 
to human meniscus, with tissue ingrowth seen in empty 
defect groups in other studies [21]. In this study the 8w 
post-surgery results were sufficiently different between 
groups such that any intrinsic healing capacity of ovine 
meniscus did not compromise the evaluation of the scaffold. 
However, by 26w post-surgery there were no difference 
between experimental groups, which could be partly related 
to the efficient intrinsic healing of the ovine meniscus.  
In this experiment we also used measurements of weight 
bearing in the operated limb to indirectly measure joint pain 
post-surgery. We have previously shown that weight bearing 
measurements can significantly differentiate between 
treatment groups post-surgery in sheep15. In this study there 
were no differences detected in weight bearing pre- and post 
surgery, nor between treatment groups, indicating that this 
surgical procedure and treatments did not cause detectable 
discomfort either immediately or for up to 8 weeks 
post-surgery. The addition of PRP to joints can cause 
inflammation. In one study multiple intra-articular PRP 
injections PRP lead to moderate/severe pain in 67% of 
Figure 11. Western Blot densitometry of A. Internal ex vivo models (EVM) B External EVM (Internal). Type I collagen and versican, 
markers of meniscal extracellular matrix are detected in both types of constructs. Markers of migrating cells (smooth muscle actin (SMA) 
and vimentin) are increased in the presence of platelet rich plasma (PRP), significantly so in the external EVM. * denotes statistically 
significant difference p<0.05. 
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patients.  In this study no differences were detected between 
groups, indicating that the inclusion of the scaffold +/- PRP 
was biocompatible and did not cause joint pain. 
In this study, a full thickness cylindrical meniscal defect 
was used to evaluate scaffold performance. This defect type 
has been previously described in small animal models [11, 26] 
and is optimal to ensure that the scaffold remains in situ 
during the experimental period. Previous studies using partial 
meniscectomy models have reported scaffold loss as a 
significant impact on the analysis of results [4]. In this study 
we could detect the remnants of the scaffold in all animals at 
8w, indicating that the scaffold was retained in the defects 
and that this defect shape is an acceptable method of scaffold 
evaluation.  
The finding that the biphasic scaffold could support tissue 
repair and that this repair was apparently accelerated by PRP 
has identified a potential use of this scaffold in meniscal 
defect repair in the clinic. However, whilst the in vivo data 
provides valuable information on the safety and 
biocompatibility of the scaffold, it does not permit evaluation 
of any mechanisms underlying meniscal repair.  In order to 
investigate mechanisms and to begin to understand the role 
of PRP in potentiating meniscal healing we constructed 
cartilage/scaffold EVM. 
The construction of EVMs for investigating regeneration 
therapies has been previously described for articular cartilage 
by our group [27]. EVM have several advantages over purely 
in vitro systems (e.g. cells seeded into scaffolds) in that the 
scaffold and any additives are in direct contact with the 
relevant damaged tissue and the architecture of the tissue 
supporting the cells is retained [28]. Our study has 
demonstrated that, when meniscal cartilage is co-cultured in 
contact with the biphasic scaffold, there is extensive 
migration of meniscal cells from the tissue into the scaffolds 
where they produce a meniscus appropriate ECM.   
It is generally accepted that endogenous tissue repair is 
driven by progenitor cells located within the tissue that 
migrate to injury sites, proliferate and deposit new matrix [29]. 
In meniscus, these mobile cells have been termed meniscal 
fibrochondrocytes (MFC) and have been previously shown to 
have a significant capacity for migration in vitro [30, 31]. There 
are, however, differences in cells isolated by enzymatic 
digestion and those grown out of meniscal explants. In the 
studies described here, the MFCs that entered the scaffolds 
are an outgrowth population, which have been shown to have 
progenitor properties in previous studies [32]. Further studies 
are underway to fully characterise the cell population 
mobilised to migrate from meniscus to scaffold in these 
experiments. 
Following damage to the meniscus, signals initiate and 
support MFC migration. It is likely that it is a combination of 
mechanical (e.g. the release of cells from a dense ECM [32]) 
and biological factors drive the recruitment of cells into the 
scaffold. It has been shown that MFCs are mobilised by 
signals found in fibrin clots [33] and that platelet derived 
growth factor (PDGF) and endothelin-1 promote migration 
of meniscal cells in vitro [30]. In this study we have 
demonstrated that the addition of PRP significantly enhanced 
the migration of the MFC into the scaffolds and increased the 
deposition of ECM within the scaffolds, as has been reported 
in other studies [12, 34]. PRP contains both fibrin and a number 
of growth factors, including PDGF, any of which could be 
acting alone or in synergy to enhance MFC migration. 
Although PRP appeared to have a slight beneficial effect on 
extracellular matrix deposition, the data was not significant 
in either model. This implies that the initial effects of PRP in 
these co-culture models is on cell migration primarily rather 
than extracellular matrix formation.  
Whilst the migratory capacity of MFC has been previously 
described, little has been reported on the mechanisms by 
which the migration is occurring.  In this study we have 
shown that three markers reported to be associated with 
repair and cell migration in connective tissue cells; vimentin, 
lumican and SMA, are expressed by the MFC captured 
within the scaffold. Vimentin, is upregulated following 
injury to tissues, exerting a pleiotropic and 
context-dependent control on cells [35]. SMA, a contractile 
actin isoform, has a role in contractile activity within cells [36] 
, and has been described in articular chondrocytes and 
meniscus [37, 38]. SMA in damaged articular cartilage [39] has 
been suggested to be a marker of the appearance of 
chondrocytes with repair capacity – “myochondrocytes” [39]. 
Lumican, a small, leucine-rich proteoglycan (SLRP) has 
been shown to play a role in tissue healing and cell migration 
[40-42] . 
No association of vimentin, SMA or lumican with healing 
has been previously reported in the meniscus.  In this study 
we demonstrate the presence of vimentin, SMA and lumican 
in meniscal tissue, mensical cells and MFC captured into 
scaffolds. We also demonstrate that PRP upregulates these 
markers in MFC captured within the scaffold, with 
significant increases occurring in the external EVM 
co-cultures compared to the internal EVM. There are no 
previous reports of the effect of PRP on these proteins in 
meniscal tissues or MFC although PRP has been shown to 
promote the migration of a number of other cell types [43, 44] 
and PRP has been shown to increase SMA associated with a 
differentiation into myofibroblasts and the promotion of 
wound contraction [45]. Our observed effects of PRP may 
provide insight into the mechanism by which PRP promotes 
Musculoskeletal Regeneration 2016; 2: e1411. doi: 10.14800/mr.1411; © 2016 by Daniel Howard, et al. 
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tissue repair and warrants further investigation. It is notable 
that vimentin, SMA and lumican were only increased 
significantly by PRP in the external EVM. It is possible that 
this is due to the cells in external EVM being relatively 
unconfined when they enter the scaffold compared to the 
space constraints of the internal EVM where only a small 
scaffold surface is offered. In this smaller scaffold space 
MFCs may experience contact inhibition between cells, 
which does not occur in the larger scaffold space offered by 
external EVM. Such ‘contact inhibition of locomotion’ [46] 
could explain the reduction in migratory capacity in response 
to stimulation by PRP detected in MFC in the reduced 
scaffold surface space. 
In conclusion, we have developed a novel biphasic 
collagen scaffold and shown that it is able to support 
meniscal repair in a defect model in vivo and to support 
meniscal cell ingrowth and ECM production in vitro. The 
addition of PRP to the scaffold enhanced healing at 2m in 
vivo and significantly enhanced MFC migration in vitro, 
possibly through the intermediary of vimentin, SMA and 
lumican. Work is currently ongoing to characterise the MFC 
populations recruited into the scaffolds and to identify 
mechanisms underlying their mobilisation. 
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